Low Tidal Volume Strategy In Cardiogenic Pulmonary Edema: The Logical Trial (LOGICAL)

Some people with heart failure develop fluid buildup in the lungs and need a breathing machine while they are treated in an intensive care unit. The amount of air delivered with each breath may affect how quickly they recover.

The LOGICAL study will compare two ways of setting the breathing machine: delivering a lower or an intermediate amount of air with each breath. About 300 adults in intensive care units across Spain will be randomly assigned to one of these strategies.

The study aims to find out whether the lower amount of air increases the number of days patients are alive and breathing without the machine during the first 28 days after assignment. The researchers will also assess other outcomes, including survival and length of stay in the intensive care unit and hospital.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

300

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Admission to a participating intensive care unit (ICU).

  2. Within the first 24 hours of invasive mechanical ventilation, whether ventilation was started before or after admission to the participating ICU.

  3. Expected duration of invasive mechanical ventilation greater than 24 hours.

  4. Acute hypoxemic respiratory failure of cardiogenic origin, meeting all three of the following criteria:

    1. PaO2/FiO2 ratio below 300 mmHg.

    2. Pulmonary congestion shown by at least one of the following:

      • Lung ultrasound showing multiple B-lines (at least 3 per zone), distributed bilaterally in at least 2 zones per hemithorax; or
      • Chest radiograph showing interstitial or alveolar edema, vascular redistribution, or Kerley B-lines.
    3. Evidence of a cardiogenic origin shown by at least one of the following:

      • Echocardiographic evidence of elevated left-sided filling pressures (E/e' >14 or E/A >2); or
      • Pulmonary capillary wedge pressure >15 mmHg measured with a pulmonary artery catheter.

Exclusion Criteria:

  1. Participation in another interventional clinical trial.
  2. More than 24 hours of invasive mechanical ventilation.
  3. Extracorporeal support already initiated.
  4. Expected extubation within the next 24 hours.
  5. A predominantly noncardiogenic cause of acute respiratory failure, including acute respiratory distress syndrome, active pneumonia or other pulmonary infection, confirmed pulmonary embolism, or acute lung injury of noncardiac origin.
  6. Pregnancy.
  7. Risk of or suspected elevated intracranial pressure.
  8. Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage IV chronic obstructive pulmonary disease.
  9. Known pre-existing interstitial lung disease.
  10. Previous pneumonectomy or lobectomy.
  11. Terminal condition, a decision to limit life-sustaining treatment, or a do-not-resuscitate order.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Low Tidal Volume Ventilation

Participants will receive volume-controlled invasive mechanical ventilation with an initial tidal volume of no more than 6 ml/kg of predicted body weight. Tidal volume may be reduced to 4 ml/kg according to respiratory mechanics and clinical tolerance.

Volume-controlled invasive mechanical ventilation with an initial tidal volume of no more than 6 mL/kg of predicted body weight. Tidal volume may be reduced stepwise to 4 mL/kg according to respiratory mechanics and clinical tolerance.

Active Comparator: Intermediate Tidal Volume Ventilation

Participants will receive volume-controlled invasive mechanical ventilation with an initial tidal volume of at least 8 mL/kg of predicted body weight. Tidal volume may be adjusted up to 10 mL/kg while maintaining airway pressures within the protocol-defined safety limits.

Volume-controlled invasive mechanical ventilation with an initial tidal volume of at least 8 mL/kg of predicted body weight. Tidal volume may be adjusted up to 10 mL/kg while maintaining plateau pressure below 30 cmH₂O and driving pressure below 15 cmH₂O.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Days Alive and Free of Invasive Mechanical Ventilation Through Day 28
Time Frame: From randomization through day 28

Number of days from randomization through day 28 that a participant is alive and free of invasive mechanical ventilation. Participants who die before day 28 are assigned 0 days. Higher values indicate a more favorable outcome.

From randomization through day 28

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
All-Cause Mortality at Day 28
Time Frame: From randomization through day 28

Percentage of participants who die from any cause within 28 days after randomization.

From randomization through day 28
Duration of Invasive Mechanical Ventilation
Time Frame: From randomization until successful liberation, death, or day 90

Time from randomization to successful liberation from invasive mechanical ventilation, defined as remaining free of invasive mechanical ventilation for at least 48 hours. Death before liberation will be considered a competing event in the analysis.

From randomization until successful liberation, death, or day 90

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Laura Amado-Rodríguez, MD, PhD, Hospital Universitario Central de Asturias

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

August 1, 2028

Study Completion (Estimated)

October 1, 2028

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • LOGICAL Trial

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

The investigators intend to explore sharing anonymized individual participant data after publication of the main results, subject to ethical approval, applicable data protection requirements, and assessment of re-identification risk. The specific data sets, access process, and availability period have not yet been determined.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.